Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows
The fear of testosterone and prostate cancer traces back to a single experiment published in 1941, and the logic that came out of that experiment has shaped clinical decisions for over eight decades, so it is worth understanding exactly what was found, why it was reasonable at the time, and why the evidence has since moved in a completely different direction.
Charles Huggins took men who had been castrated and who already had advanced metastatic prostate cancer, injected them with testosterone, and watched their cancer markers rise. The medical community drew what seemed like a sensible conclusion: if removing testosterone slows the cancer, adding testosterone must accelerate it. Huggins won the Nobel Prize in 1966 for that work, which cemented the idea into the foundation of urology for generations.
The part of that logic that holds up is this: prostate cancer that has already spread is often what is called androgen-sensitive, meaning it uses testosterone as fuel, and for those men castration is still a legitimate treatment today.
The part that does not hold up is the leap from "testosterone feeds an existing metastatic cancer in a castrated man" to "testosterone causes prostate cancer in healthy men."
That leap ignored something called the saturation model, which is the idea that prostate tissue has a ceiling for how much testosterone it can actually respond to. The androgen receptors inside prostate cells can only process so much hormone before they are fully occupied and additional testosterone produces no further effect. That ceiling sits at roughly 240 to 250 nanograms per deciliter of testosterone in the blood.
Think of it like a parking lot. Once every space is filled, more cars arriving changes nothing inside the lot. A castrated man has almost no testosterone, so starting from zero, any testosterone you add is like filling empty parking spaces and the prostate responds dramatically. But a healthy man with testosterone levels already in the normal range is already above that ceiling, so giving him more does not give the prostate more signal because there are no empty spaces left.
TRT keeps a hypogonadal man above 250 ng/dL. That is the relevant number. The 1941 experiment was conducted entirely below that ceiling, which is why the results looked so alarming, and why applying them to men with functional testosterone production was always a scientific error.
What happens when you actually run the studies on men receiving TRT at therapeutic levels?
The largest randomized trial to date followed 5,204 men across 33 months and compared prostate cancer rates between men receiving testosterone replacement and men receiving a placebo. Prostate cancer developed in 0.46 percent of the TRT group and 0.42 percent of the placebo group. The hazard ratio was 1.07 with a p-value of 0.87, which means there was no statistical difference at all and the result was about as close to a null finding as you can get.
A population-level study of 78,615 men with 18 years of follow-up found something that goes even further: men who used TRT had lower prostate cancer-specific mortality, with a hazard ratio of 0.52, meaning TRT users were roughly half as likely to die from prostate cancer compared to non-users. That is not a causal claim because observational data cannot establish causation, but it is directly contrary to the hypothesis that testosterone drives prostate cancer death.
A meta-analysis of 28 randomized controlled trials looked at PSA, which is something called prostate-specific antigen, a protein produced by prostate cells that is used as a marker for prostate stress or abnormal growth. Across all 28 trials, TRT raised PSA by an average of 0.08 nanograms per milliliter, which is a change so small it is considered clinically meaningless. The same analysis found that lower urinary tract symptom scores changed by exactly zero.
The most direct test of the concern, though, is what happens when you give testosterone to men who already have prostate cancer. If testosterone causes prostate cancer, it should make existing disease worse, cause recurrence, or accelerate death. A study of 69,984 men who had been treated for localized prostate cancer identified 1,012 of them who subsequently received TRT. There was no increase in cancer recurrence and no increase in death compared to those who did not receive TRT.
That finding is worth sitting with. If testosterone does not cause existing treated prostate cancer to come back and grow, the argument that it initiates cancer in healthy tissue becomes very hard to sustain.
The practical takeaway is straightforward. Before starting TRT, get a baseline PSA measurement. Recheck it at three to six months and then annually after that. The Endocrine Society's clinical practice guidelines suggest referral to a urologist if PSA rises more than 1.4 nanograms per milliliter above that baseline, because a jump that large warrants investigation regardless of its cause. That monitoring protocol is not because TRT is dangerous to the prostate, it is because the prostate is an organ that warrants surveillance in aging men and TRT should not be a reason to stop watching it.
The 1941 experiment was not wrong about what it observed. In a castrated man with metastatic prostate cancer, testosterone injection raised cancer markers. That was a real finding. The error was a generalization, applying a result from an extreme, below-threshold population to an entirely different context, and then holding that generalization for 80 years without adequate testing.
The reason this matters is not just academic. Men who need testosterone replacement are weighing real tradeoffs, and a fear built on a misapplied 1941 observation is not a real tradeoff. The data accumulated since then does not show a signal in the direction of harm. Eight decades of clinical decisions rested on a logical error, not on a reproducible finding in the population it was applied to, and that is exactly the kind of thing that is worth understanding before you make a decision about your own health.
References
- Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
- Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
- Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
- Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
- Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
- Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
- Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.